Exploiting epigenetics for the treatment of inborn errors of metabolism
- PMID: 30916397
- PMCID: PMC7041640
- DOI: 10.1002/jimd.12093
Exploiting epigenetics for the treatment of inborn errors of metabolism
Abstract
Gene therapy is currently considered as the optimal treatment for inborn errors of metabolism (IEMs), as it aims to permanently compensate for the primary genetic defect. However, emerging gene editing approaches such as CRISPR-Cas9, in which the DNA of the host organism is edited at a precise location, may have outperforming therapeutic potential. Gene editing strategies aim to correct the actual genetic mutation, while circumventing issues associated with conventional compensation gene therapy. Such strategies can also be repurposed to normalize gene expression changes that occur secondary to the genetic defect. Moreover, besides the genetic causes of IEMs, it is increasingly recognized that their clinical phenotypes are associated with epigenetic changes. Because epigenetic alterations are principally reversible, this may offer new opportunities for treatment of IEM patients. Here, we present an overview of the promises of epigenetics in eventually treating IEMs. We discuss the concepts of gene and epigenetic editing, and the advantages and disadvantages of current and upcoming gene-based therapies for treatment of IEMs.
Keywords: (epi)genome editing; DNA methylation; gene correction; histone modifications; inherited metabolic disease; therapy development.
© 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Conflict of interest statement
The authors declare no potential conflict of interest.
Figures


References
-
- Lee YM, Conlon TJ, Specht A, et al. Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia. J Inherit Metab Dis. 2018;41:977‐984. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical